Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04141228 · ClinicalTrials.gov registry record
A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 28,000
- Enrollment target
NCT04141228 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 28,000 participants.
The verdict
NCT04141228 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 28,000 participants
- Enrollment target
Study Summary
A study involving real-world database analysis to evaluate the hospital healthcare utilization and costs, and all-cause, major bleeding-, clinically relevant bleeding-, any bleeding-, and venous thromboembolism (VTE)-related hospital readmissions among hospitalized VTE patients treated with apixaban or warfarin, with or without low molecular weight heparin (LMWH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28,000 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2018-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04141228
The ClinicalTrials.gov registry entry for NCT04141228 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04141228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04141228 about?
NCT04141228 is a clinical study titled "A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US". A study involving real-world database analysis to evaluate the hospital healthcare utilization and costs, and all-cause, major bleeding-, clinically relevant bleeding-, any bleeding-, and venous thromboembolism (VTE)-related hospital readmissions among hospitalized VTE patients treated with apixaban...
What is the current status of trial NCT04141228?
This trial is currently completed. The enrollment target is 28,000 participants. The study started on 2016-11-29. Estimated completion is 2018-05-31.
Who is sponsoring clinical trial NCT04141228?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.